Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016432 · ClinicalTrials.gov registry record · Phase 3
Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen
A Phase 3 study of Breast Cancer, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,598
- Enrollment target
- 20
- Study locations
NCT00016432: Completed Phase 3 study of Breast Cancer, sponsored by NSABP Foundation.
NCT00016432 is a Phase 3 study of Breast Cancer that has completed, run by NSABP Foundation. The registered enrollment target is 1,598 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016432, a Phase 3 study of Breast Cancer, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,598 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen by the tumor cells. It is not yet known whether exemestane is effective in preventing the recurrence of breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of exemestane in preventing cancer recurrence in postmenopausal women who have resected stage I, stage II, or stage IIIA breast cancer and have completed 5 years of tamoxifen.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG exemestane
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- California Cancer Center - Fresno
- Sutter Health Western Division Cancer Research Group - Greenbrae
- Scripps Cancer Center - La Jolla
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Loma Linda University Cancer Institute - Loma Linda
- Pacific Shores Medical Group - Long Beach
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Chao Family Comprehensive Cancer Center - Orange
- Comprehensive Cancer Centers of the Desert - Palm Springs
- Sutter Cancer Center - Sacramento
- Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego - San Diego
- CCOP - Santa Rosa Memorial Hospital - Santa Rosa
- Stanford University Medical Center - Stanford
- Kaiser Permanente Medical Center - Vallejo - Vallejo
Colorado
- University of Colorado Cancer Center - Denver
- CCOP - Colorado Cancer Research Program, Incorporated - Denver
Alabama
- Comprehensive Cancer Institute of Huntsville - Huntsville
Arizona
- CCOP - Greater Phoenix - Phoenix
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,598 participants |
| Start Date | 2001-05 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
What the finished NCT00016432 record still lists
NCT00016432 is an interventional study that assigns participants to a tested intervention. Its 1,598 participants enrollment target places it among the larger protocols in the corpus, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00016432 names 20 study sites across 5 states, led by California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT00016432 about?
NCT00016432 is a clinical study titled "Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen by the tumor cells. It is not yet known whether exemestane is effective in preventing the recurrence of breast cancer. PURPOSE: Random...
What is the current status of trial NCT00016432?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,598 participants. The study started on 2001-05. Estimated completion is 2011-02.
What conditions does trial NCT00016432 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00016432?
The interventions under investigation include: Placebo (DRUG), exemestane (DRUG).
Who is sponsoring clinical trial NCT00016432?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00016432 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00016432's enrollment target sits among peer trials
1,598 81st of 1224 higher than 1,144 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia